Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3832479 · 2 trials · 1 indication
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to tlast (AUC\[0-tlast\]) of LY3832479.
PK: Maximum Serum Concentration (Cmax) of LY3832479.
The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Arm | Type | Description |
|---|---|---|
| LY3832479 | EXPERIMENTAL | Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479. |
| Placebo | PLACEBO_COMPARATOR | Participants received single subcutaneous dose of Placebo. |
| Name | Type | Description |
|---|---|---|
| LY3832479 | DRUG | Administered subcutaneously |
| Placebo | DRUG | Administered subcutaneously |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history and physical examination * Are willing to follow study procedures, including having nasal or nasopharyngeal swabs collected * Have a body mass index (BMI) within the range of greater than or equa...
LY3832479 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy participants. Two Phase 1 trials have been completed, with a total enrollment of 44 participants.
LY3832479 is being studied for use in healthy participants, as part of early clinical development. The completed Phase 1 trials evaluated the drug in healthy volunteers to assess its safety and tolerability.
LY3832479 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker LLY. The company is conducting clinical trials to evaluate this investigational drug.
LY3832479 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and the drug is not yet approved. It remains investigational and is being studied in healthy participants.
LY3832479 has been studied in two completed Phase 1 trials: NCT04441931 and NCT04611789. Both trials enrolled healthy participants in the United States, with a minimum age of 18 years, and were placebo-controlled and double-blind.
Yes, LY3832479 is also known as LY-CoV016. The clinical trial titles refer to the drug as LY3832479 (LY-CoV016), indicating that both names are used for the same investigational drug.